ImmunoGen, Inc. (IMGN) News

ImmunoGen, Inc. (IMGN): $31.23

0.00 (0.00%)

POWR Rating

Component Grades








Add IMGN to Watchlist
Sign Up

Industry: Biotech




#61 of 345

in industry

Filter IMGN News Items

IMGN News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

IMGN News Highlights

  • For IMGN, its 30 day story count is now at 18.
  • Over the past 21 days, the trend for IMGN's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
  • DRUG, ABBV and ASH are the most mentioned tickers in articles about IMGN.

Latest IMGN News From Around the Web

Below are the latest news stories about IMMUNOGEN INC that investors may wish to consider to help them evaluate IMGN as an investment opportunity.

3 Stocks at the Forefront of Medical Innovation

Boring businesses and industries typically show new faces when technology comes around; today, these biotech stocks are leading the way.

Gabriel Osorio-Mazzilli on InvestorPlace | December 26, 2023

AbbVie's Recent ImmunoGen Acquisition Looks Brilliant: Here's Why

The acquisition fills an immediate need with some extras to boot.

Yahoo | December 26, 2023

Are Investors Undervaluing ImmunoGen, Inc. (NASDAQ:IMGN) By 38%?

Key Insights The projected fair value for ImmunoGen is US$47.87 based on 2 Stage Free Cash Flow to Equity Current share...

Yahoo | December 22, 2023

The 7 Most Undervalued Growth Stocks to Buy in December

Stocks of a lot of well-known and historically great companies are on sale right now.

Joel Baglole on InvestorPlace | December 13, 2023

AbbVie Just Followed Pfizer's Big Move. Here's What It Means For Investors

It's making a major acquisition to beef up a key area of its pipeline.

Yahoo | December 12, 2023

While AbbVie Is Busy Investing in Growth, How Tradable Is it?

Remember AbbVie ? On November 30, AbbVie announced plans to acquire ImmunoGen in a roughly $10.1B all-cash transaction. ImmunoGen already manufactures and markets Elahere, which is an antibody-drug conjugate, in fact the first of its kind approved for the treatment of platinum-resistant ovarian cancer.

Yahoo | December 11, 2023

The 3 Best Cheap Stocks to Buy in December

Investors wanting to buy low and sell high should consider a position in one of these great companies whose shares have pulled back lately.

Joel Baglole on InvestorPlace | December 10, 2023

ImmunoGen Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH

WALTHAM, Mass., December 10, 2023--ImmunoGen Presents Findings from Newly Diagnosed AML Cohorts in Phase 1b/2 Study of Pivekimab Sunirine with Azacitidine and Venetoclax at ASH

Yahoo | December 10, 2023

AbbVie Just Announced 2 Big Acquisitions: Is This Dividend King a No-Brainer Buy Right Now?

AbbVie's share price reflected the concerns. AbbVie's executives and business development team have been quite busy lately. On Nov. 30, AbbVie announced its plans to acquire ImmunoGen (NASDAQ: IMGN) in an all-cash transaction valued at roughly $10.1 billion.

Yahoo | December 10, 2023

Market Movers: Why Big Players Are Investing Millions in These 3 Stocks

In investing, certain stocks catch the discerning eye of big players, drawing in substantial investments.

Yiannis Zourmpanos on InvestorPlace | December 8, 2023

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!